Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Inflammatory biomarkers in patients in Simvastatin treatment : No effect of co-enzyme Q10 supplementation. / Hansen, Maria; Kuhlman, Anja C.B.; Sahl, Ronni E.; Kelly, Bo; Morville, Thomas; Dohlmann, Tine L.; Chrøis, Karoline M.; Larsen, Steen; Helge, Jørn W.; Dela, Flemming.
I: Cytokine, Bind 113, 2019, s. 393-399.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Inflammatory biomarkers in patients in Simvastatin treatment
T2 - No effect of co-enzyme Q10 supplementation
AU - Hansen, Maria
AU - Kuhlman, Anja C.B.
AU - Sahl, Ronni E.
AU - Kelly, Bo
AU - Morville, Thomas
AU - Dohlmann, Tine L.
AU - Chrøis, Karoline M.
AU - Larsen, Steen
AU - Helge, Jørn W.
AU - Dela, Flemming
N1 - Corrigendum: www.sciencedirect.com/science/article/pii/S1043466619303709?via%3Dihub
PY - 2019
Y1 - 2019
N2 - Purpose: Atherosclerosis is a major risk factor for cardiovascular disease (CVD) and is known to be an inflammatory process. Statin therapy decreases both cholesterol and inflammation and is used in primary and secondary prevention of CVD. However, a statin induced decrease of plasma concentrations of the antioxidant coenzyme Q10 (CoQ10), may prevent the patients from reaching their optimal anti-inflammatory potential. Here, we studied the anti-inflammatory effect of Simvastatin therapy and CoQ10 supplementation. Methods: 35 patients in primary prevention with Simvastatin (40 mg/day) were randomized to receive oral CoQ10 supplementation (400 mg/d) or placebo for 8 weeks. 20 patients with hypercholesterolemia who received no cholesterol-lowering treatment was a control group. Plasma concentrations of lipids and inflammatory biomarkers (interleukin-6 (IL6); -8 (IL8); -10 (IL10), tumor necrosis factor-α (TNFα); high-sensitivity C reactive protein (hsCRP)) as well as glycated hemoglobin (HbA1c) were quantified before and after the intervention. Results: No significant change in inflammatory markers or lipids was observed after CoQ10 supplementation Patients in Simvastatin therapy had significantly (P < 0.05) lower baseline concentration of IL6 (0.31 ± 0.03 pg/ml), IL8 (1.6 ± 0.1 pg/ml) IL10 (0.16 ± 0.02 pg/ml) and borderline (P = 0.053) lower TNFα (0.88 ± 0.05 pg/ml), but not hsCRP (1.34 ± 0.19 mg/l) compared with the control group (0.62 ± 0.08, 2.6 ± 0.2, 0.25 ± 0.01, 1.07 ± 0.09, and 1.90 ± 0.35, respectively). Conclusions: Simvastatin therapy has beneficial effects on inflammatory markers in plasma, but CoQ10 supplementation seems to have no additional potentiating effect in patients in primary prevention. In contrast, glucose homeostasis may improve with CoQ10 supplementation.
AB - Purpose: Atherosclerosis is a major risk factor for cardiovascular disease (CVD) and is known to be an inflammatory process. Statin therapy decreases both cholesterol and inflammation and is used in primary and secondary prevention of CVD. However, a statin induced decrease of plasma concentrations of the antioxidant coenzyme Q10 (CoQ10), may prevent the patients from reaching their optimal anti-inflammatory potential. Here, we studied the anti-inflammatory effect of Simvastatin therapy and CoQ10 supplementation. Methods: 35 patients in primary prevention with Simvastatin (40 mg/day) were randomized to receive oral CoQ10 supplementation (400 mg/d) or placebo for 8 weeks. 20 patients with hypercholesterolemia who received no cholesterol-lowering treatment was a control group. Plasma concentrations of lipids and inflammatory biomarkers (interleukin-6 (IL6); -8 (IL8); -10 (IL10), tumor necrosis factor-α (TNFα); high-sensitivity C reactive protein (hsCRP)) as well as glycated hemoglobin (HbA1c) were quantified before and after the intervention. Results: No significant change in inflammatory markers or lipids was observed after CoQ10 supplementation Patients in Simvastatin therapy had significantly (P < 0.05) lower baseline concentration of IL6 (0.31 ± 0.03 pg/ml), IL8 (1.6 ± 0.1 pg/ml) IL10 (0.16 ± 0.02 pg/ml) and borderline (P = 0.053) lower TNFα (0.88 ± 0.05 pg/ml), but not hsCRP (1.34 ± 0.19 mg/l) compared with the control group (0.62 ± 0.08, 2.6 ± 0.2, 0.25 ± 0.01, 1.07 ± 0.09, and 1.90 ± 0.35, respectively). Conclusions: Simvastatin therapy has beneficial effects on inflammatory markers in plasma, but CoQ10 supplementation seems to have no additional potentiating effect in patients in primary prevention. In contrast, glucose homeostasis may improve with CoQ10 supplementation.
KW - Antioxidant
KW - Dyslipidemia
KW - Hemoglobin A1C
KW - Inflammation
UR - https://www.sciencedirect.com/science/article/pii/S1043466619303709?via%3Dihub
U2 - 10.1016/j.cyto.2018.10.011
DO - 10.1016/j.cyto.2018.10.011
M3 - Journal article
C2 - 30389229
AN - SCOPUS:85055703293
VL - 113
SP - 393
EP - 399
JO - Cytokine
JF - Cytokine
SN - 1043-4666
ER -
ID: 214948850